<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The cyclooxygenases COX-1 and COX-2 catalyze the first committed step of <z:chebi fb="11" ids="26333">prostaglandin</z:chebi> synthesis from <z:chebi fb="0" ids="15843">arachidonic acid</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Previous studies in rodent <z:hpo ids='HP_0001297'>stroke</z:hpo> models have shown that the inducible COX-2 isoform promotes neuronal injury, and the administration of COX-2 inhibitors reduces <z:mpath ids='MPATH_124'>infarct</z:mpath> volume </plain></SENT>
<SENT sid="2" pm="."><plain>We investigated the function of <z:chebi fb="0" ids="15551">PGE2</z:chebi>, a principal <z:chebi fb="11" ids="26333">prostaglandin</z:chebi> product of COX-2 enzymatic activity, in neuronal survival in <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="15551">PGE2</z:chebi> exerts its downstream effects by signaling through a class of four distinct G-protein-coupled EP receptors (for E-<z:chebi fb="0" ids="26347">prostanoid</z:chebi>: EP1, EP2, EP3, and EP4) that have divergent effects on cAMP and phosphoinositol turnover and different anatomical distributions in brain </plain></SENT>
<SENT sid="4" pm="."><plain>The EP2 receptor subtype is abundantly expressed in cerebral cortex, striatum, and hippocampus, and is positively coupled to cAMP production </plain></SENT>
<SENT sid="5" pm="."><plain>In vitro studies of dispersed neurons and organotypic hippocampal cultures demonstrated that activation of the EP2 receptor was neuroprotective in paradigms of <z:chebi fb="0" ids="31882">NMDA</z:chebi> toxicity and oxygen <z:chebi fb="105" ids="17234">glucose</z:chebi> deprivation </plain></SENT>
<SENT sid="6" pm="."><plain>Pharmacologic blockade of EP2 signaling by inhibition of protein kinase A activation reversed this protective effect, suggesting that EP2-mediated neuroprotection is dependent on cAMP signaling </plain></SENT>
<SENT sid="7" pm="."><plain>In the middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>-reperfusion model of transient forebrain <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, genetic deletion of the EP2 receptor significantly increased <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> in cerebral cortex and subcortical structures </plain></SENT>
<SENT sid="8" pm="."><plain>These studies indicate that activation of the <z:chebi fb="0" ids="15551">PGE2</z:chebi> EP2 receptor can protect against excitotoxic and anoxic injury in a cAMP-dependent manner </plain></SENT>
<SENT sid="9" pm="."><plain>Taken together, these data suggest a novel mechanism of neuroprotection mediated by a dominant <z:chebi fb="0" ids="15551">PGE2</z:chebi> receptor subtype in brain that may provide a target for therapeutic intervention </plain></SENT>
</text></document>